Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma.

MLA

Li, Meng, et al. “Disparity in Initiation of Checkpoint Inhibitors among Commercially Insured and Medicare Advantage Patients with Metastatic Melanoma.” Journal of Managed Care & Specialty Pharmacy, vol. 29, no. 11, Nov. 2023, pp. 1232–41. EBSCOhost, https://doi.org/10.18553/jmcp.2023.29.11.1232.

APA

Li, M., Liao, K., Nowakowska, M., Wehner, M., & Shih, Y.-C. T. (2023). Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma. Journal of Managed Care & Specialty Pharmacy, 29(11), 1232–1241. https://doi.org/10.18553/jmcp.2023.29.11.1232

Chicago

Li, Meng, Kaiping Liao, Malgorzata Nowakowska, Mackenzie Wehner, and Ya-Chen Tina Shih. 2023. “Disparity in Initiation of Checkpoint Inhibitors among Commercially Insured and Medicare Advantage Patients with Metastatic Melanoma.” Journal of Managed Care & Specialty Pharmacy 29 (11): 1232–41. doi:10.18553/jmcp.2023.29.11.1232.